FDA approves IDE learn about to judge HeartWare Ventricular Facilitate Group
Posted in Medical Condition on September 4th, 2010HeartWare Universal, Inc. (Nasdaq: HTWR; ASX: HIN), a best innovator of less invasive, miniaturized circulatory endure technologies that are revolutionizing the treatment of advanced determination insolvency, today announced that the U.S. Grub and Painkiller Conduct (FDA) has approved an IDE (Investigational Apparatus Dispensation Supplementation that allows HeartWare to enroll a deficient tract of 54 patients in its "ADVANCE" bridge-to-transplant Read the rest of this entry »
